ATE173725T1 - Azazyklische verbindungen - Google Patents
Azazyklische verbindungenInfo
- Publication number
- ATE173725T1 ATE173725T1 AT93917877T AT93917877T ATE173725T1 AT E173725 T1 ATE173725 T1 AT E173725T1 AT 93917877 T AT93917877 T AT 93917877T AT 93917877 T AT93917877 T AT 93917877T AT E173725 T1 ATE173725 T1 AT E173725T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- 6alkyl
- conrarb
- conr13c2
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929216065A GB9216065D0 (en) | 1992-07-28 | 1992-07-28 | Therapeutic agents |
| GB929216304A GB9216304D0 (en) | 1992-07-31 | 1992-07-31 | Therapeutic agents |
| GB929224918A GB9224918D0 (en) | 1992-11-27 | 1992-11-27 | Therapeutic agents |
| GB929226058A GB9226058D0 (en) | 1992-12-14 | 1992-12-14 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE173725T1 true ATE173725T1 (de) | 1998-12-15 |
Family
ID=27450911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93917877T ATE173725T1 (de) | 1992-07-28 | 1993-07-20 | Azazyklische verbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5561130A (de) |
| EP (1) | EP0652866B1 (de) |
| JP (1) | JPH07508993A (de) |
| AT (1) | ATE173725T1 (de) |
| AU (1) | AU675447B2 (de) |
| CA (1) | CA2138650A1 (de) |
| DE (1) | DE69322275T2 (de) |
| ES (1) | ES2124318T3 (de) |
| WO (1) | WO1994002461A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9402688D0 (en) * | 1994-02-11 | 1994-04-06 | Merck Sharp & Dohme | Therapeutic agents |
| US5750549A (en) * | 1996-10-15 | 1998-05-12 | Merck & Co., Inc. | Cycloalkyl tachykinin receptor antagonists |
| US7169372B1 (en) | 2000-07-03 | 2007-01-30 | Zakrytoe Aktsionernoe Obschestvo “OSTIM” | Method for producing nano-sized crystalline hydroxyapatite |
| KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ， インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
| JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0606985D0 (en) * | 2006-04-07 | 2006-05-17 | Merck Sharp & Dohme | Therapeutic agents |
| WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CA2674436C (en) | 2007-01-10 | 2012-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| EP2145884B1 (de) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledionderivat |
| CA2690191C (en) | 2007-06-27 | 2015-07-28 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| EP2429296B1 (de) | 2009-05-12 | 2017-12-27 | Albany Molecular Research, Inc. | 7-([1,2,4,]triazol[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorphenyl)-1,2,3,4- tetrahydroisochinolin und seine verwendung |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| MX2011011901A (es) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas. |
| EA023838B1 (ru) | 2009-10-14 | 2016-07-29 | Мерк Шарп Энд Домэ Корп. | ЗАМЕЩЕННЫЕ ПИПЕРИДИНЫ, КОТОРЫЕ ПОВЫШАЮТ АКТИВНОСТЬ p53, И ИХ ПРИМЕНЕНИЕ |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (de) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina) |
| CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (de) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| WO2012036997A1 (en) | 2010-09-16 | 2012-03-22 | Schering Corporation | Fused pyrazole derivatives as novel erk inhibitors |
| EP3766975A1 (de) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| CN103732592A (zh) | 2011-04-21 | 2014-04-16 | 默沙东公司 | 胰岛素样生长因子-1受体抑制剂 |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP2844261B1 (de) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
| AU2013361694B2 (en) | 2012-12-20 | 2017-10-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2016025322A1 (en) * | 2014-08-09 | 2016-02-18 | Purdue Research Foundation | Design and development of neurokinin-1 receptor-binding agent delivery conjugates |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2922591A1 (de) * | 1979-06-02 | 1980-12-04 | Basf Ag | Verfahren zur herstellung von pyrazolen |
| GB8824400D0 (en) * | 1988-10-18 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
| DE3918979A1 (de) * | 1989-06-10 | 1990-12-13 | Basf Ag | Verfahren zur herstellung von pyrazol und dessen derivaten |
| UA41251C2 (uk) * | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі |
| DE4028393A1 (de) * | 1990-09-07 | 1992-03-12 | Basf Ag | Verfahren zur herstellung von 3-methylpyrazol |
| EP0499313B1 (de) * | 1991-02-11 | 1997-06-11 | MERCK SHARP & DOHME LTD. | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung |
| ATE136885T1 (de) * | 1991-08-20 | 1996-05-15 | Merck Sharp & Dohme | Azacyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
-
1993
- 1993-07-20 US US08/379,622 patent/US5561130A/en not_active Expired - Fee Related
- 1993-07-20 AU AU47139/93A patent/AU675447B2/en not_active Ceased
- 1993-07-20 CA CA002138650A patent/CA2138650A1/en not_active Abandoned
- 1993-07-20 EP EP93917877A patent/EP0652866B1/de not_active Expired - Lifetime
- 1993-07-20 DE DE69322275T patent/DE69322275T2/de not_active Expired - Fee Related
- 1993-07-20 ES ES93917877T patent/ES2124318T3/es not_active Expired - Lifetime
- 1993-07-20 AT AT93917877T patent/ATE173725T1/de not_active IP Right Cessation
- 1993-07-20 WO PCT/GB1993/001525 patent/WO1994002461A1/en active IP Right Grant
- 1993-07-20 JP JP6503945A patent/JPH07508993A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07508993A (ja) | 1995-10-05 |
| EP0652866A1 (de) | 1995-05-17 |
| DE69322275D1 (de) | 1999-01-07 |
| AU4713993A (en) | 1994-02-14 |
| AU675447B2 (en) | 1997-02-06 |
| CA2138650A1 (en) | 1994-02-03 |
| ES2124318T3 (es) | 1999-02-01 |
| EP0652866B1 (de) | 1998-11-25 |
| WO1994002461A1 (en) | 1994-02-03 |
| US5561130A (en) | 1996-10-01 |
| DE69322275T2 (de) | 1999-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE173725T1 (de) | Azazyklische verbindungen | |
| ES2163410T3 (es) | Derivados de benzodiazepina. | |
| DE69516853D1 (de) | Aralkoxy und aralkylthio substituierte azacyclische verbindungen als tachykinin antagonisten | |
| WO1993001165A3 (en) | Aromatic compounds, compositions containing them and their use in therapy | |
| ATE163180T1 (de) | N-phenylpyrazole als insektizide und akarizide | |
| DK357980A (da) | Fremgangsmaade til fremstilling af propenylaminer | |
| NO924783D0 (no) | Terapeutiske midler | |
| ES2093523T3 (es) | Catalizadores quirales y reacciones de epoxidacion catalizadas por los mismos. | |
| DK0553016T3 (da) | Hidtil ukendte naphtalenamider og -sulfonamider, fremgangsmåder til deres fremstilling samt farmaceutiske midler indeholdende dem | |
| DE69303583T2 (de) | 15-Deoxyspergualin analoge Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Therapeutika zur Unterdrückung der Immunabwehr | |
| DE69414106D1 (de) | Herbizide verbindungen | |
| DK0749438T3 (da) | Hidtil ukendte silylforbindelser og deres anvendelse | |
| PT689534E (pt) | Derivados amida como ligandos de 5-ht1a | |
| ATE71948T1 (de) | Guanidin-verbindungen, die ein substituiertes tetraphenylboration enthalten, verfahren zu deren herstellung und verwendung dieser verbindungen waehrend der peptid-synthese. | |
| FI913713A0 (fi) | Nya bicykliska aminosubstituerade foereningar. | |
| ES2083162T3 (es) | Fosfinita-boranos quirales, su preparacion y utilizacion. | |
| ES8900162A1 (es) | Procedimiento para la obtencion de 3-acilaminobenzisotiazol-s,s-dioxidos | |
| DK32287D0 (da) | 3-acylaminomethyl-imidazo(1,2-a)pyridinderivater, fremgangsmaade til fremstilling deraf samt laegemiddel indeholdende saadanne derivater | |
| SE8404906L (sv) | Fluoralkylerade karbapenemderivat | |
| DE59409645D1 (en) | Substituierte arylthioalkylthiopyridine | |
| GB9226857D0 (en) | Pharmaceutical compositions | |
| ES2149216T3 (es) | Utilizacion de derivados de piperazina para el tratamiento de trastornos cognoscitivos. | |
| NO962251L (no) | Substituerte aminoalkyaminopyridiner | |
| DK0599732T3 (da) | 1-phenylbicyklo 2.2.2 octanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem. | |
| DE69715864D1 (de) | Verfahren zur herstellung von halogenierten derivaten des 2-amino oder 2-acetamido trifluormethylbenzols |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |